1,4-difluorobicyclo<2.2.2>octane | 20277-40-1

• 分子结构分类: 有机化合物 - 有机卤素化合物 - 有机氟化物
• 英文名称: 1,4-difluorobicyclo<2.2.2>octane
• 英文别名: 1,4-Difluor-bicyclo<2.2.2>octan；1,4-Difluorbicyclo<2.2.2>octan；1,4-Difluorobicyclo[2.2.2]octane
• CAS: 20277-40-1
• 化学式: C₈H₁₂F₂
• 分子量: 146.18
• InChiKey: BYTCFKXDXCWSGA-UHFFFAOYSA-N

物化性质

• 熔点：
  193-195 °C
• 沸点：
  144.5±20.0 °C(Predicted)
• 密度：
  1.08±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1,4-difluorobicyclo<2.2.2>octane 、 N-氯代丁二酰亚胺 、 溶剂黄146 以34%的产率得到
  参考文献：
  名称：

  ADCOCK, W.;ABEYWICKREMA, A. N., J. ORG. CHEM., 1982, 47, N 15, 2951-2957

  摘要：

  DOI：
• 作为产物：
  描述：

  双环[2.2.2]辛烷-1,4-二醇 在 N,N-二乙基(2-氯-1,1,2-三氟乙基)胺 作用下， 反应 1.0h， 以49%的产率得到1,4-difluorobicyclo<2.2.2>octane
  参考文献：
  名称：

  Kopecky, Jan; Smejkal, Jaroslav, Collection of Czechoslovak Chemical Communications, 1980, vol. 45, # 11, p. 2971 - 2975

  摘要：

  DOI：

文献信息

• SUBSTITUTED 2-(CHROMAN-6-YLOXY)-THIAZOLES AND THEIR USE AS PHARMACEUTICALS
  申请人：CZECHTIZKY Werngard

  公开号：US20130065859A1

  公开（公告）日：2013-03-14

  The present invention relates to substituted 2-(chroman-6-yloxy)-thiazoles of the formula I, in which Ar, R2, R3 and R4 are as defined in the claims. The compounds of the formula I are inhibitors of the sodium-calcium exchanger (NCX), especially of the sodium-calcium exchanger of subtype 1 (NCX1), and are suitable for the treatment of diverse disorders in which intracellular calcium homeostasis is disturbed, such as arrhythmias, heart failure and stroke. The invention furthermore relates to processes for the preparation of the compounds of the formula I, their use as pharmaceuticals, and pharmaceutical compositions comprising them.

  本发明涉及式I的取代2-(色甘醇-6-氧基)-噻唑衍生物，其中Ar、R2、R3和R4如权利要求中所定义。式I的化合物是钠-钙交换蛋白（NCX）的抑制剂，特别是亚型1的钠-钙交换蛋白（NCX1），适用于处理细胞内钙离子稳态受扰的各种疾病，如心律失常、心力衰竭和中风。本发明还涉及制备式I的化合物的方法，它们作为药物的用途，以及包含它们的药物组合物。
• SUBSITUTED 2-(CHROMAN-6-YLOXYL)-THIAZOLES AND THEIR USE AS PHARMACEUTICALS
  申请人：Sanofi

  公开号：US20140243292A1

  公开（公告）日：2014-08-28

  The present invention relates to substituted 2-(chroman-6-yloxy)-thiazoles of the formula I, in which Ar, R2, R3 and R4 are as defined in the claims. The compounds of the formula I are inhibitors of the sodium-calcium exchanger (NCX), especially of the sodium-calcium exchanger of subtype 1 (NCX1), and are suitable for the treatment of diverse disorders in which intracellular calcium homeostasis is disturbed, such as arrhythmias, heart failure and stroke. The invention furthermore relates to processes for the preparation of the compounds of the formula I, their use as pharmaceuticals, and pharmaceutical compositions comprising them.

  本发明涉及式I的取代2-(色烯-6-氧基)-噻唑，其中Ar，R2，R3和R4如权利要求所定义。公式I化合物是钠钙交换器（NCX）的抑制剂，特别是钠钙交换器亚型1（NCX1）的抑制剂，并适用于治疗细胞内钙离子稳态受到干扰的多种疾病，如心律失常，心力衰竭和中风。本发明还涉及制备公式I化合物的方法，它们作为药物的用途，以及包含它们的制药组合物。
• Substituted chroman-6-yloxy-cycloalkanes and their use as pharmaceuticals
  申请人：SANOFI

  公开号：US20160016928A1

  公开（公告）日：2016-01-21

  The present invention relates to substituted chroman-6-yloxy-cycloalkanes of the formula (I) in which Ar, R1 to R4, p and q are as defined in the claims. The compounds of the formula (I) are inhibitors of the sodium-calcium exchanger (NCX), especially of the sodium-calcium exchanger of subtype 1 (NCX1), and are suitable for the treatment of diverse disorders in which intracellular calcium homeostasis is disturbed, such as arrhythmias, heart failure and stroke. The invention furthermore relates to processes for the preparation of the compounds of the formula (I), their use as pharmaceuticals, and pharmaceutical compositions comprising them.

  本发明涉及式(I)中的取代的色甘醇-6-氧基环烷烃，其中Ar，R1至R4，p和q如权利要求中所定义。式(I)化合物是钠钙交换器（NCX）的抑制剂，特别是钠钙交换器的亚型1（NCX1），适用于治疗各种细胞内钙平衡紊乱的疾病，如心律失常、心力衰竭和中风。本发明还涉及制备式(I)化合物的方法，它们作为药物的使用以及包含它们的制药组合物。
• Substituted 2-(chroman-6-yloxy)-thiazoles and their use as pharmaceuticals
  申请人：SANOFI

  公开号：EP2567958B1

  公开（公告）日：2014-10-29
• Synthesis of 4-substituted bicyclo[2.2.2]oct-1-yl fluorides
  作者：William Adcock、Anil N. Abeywickrema

  DOI：10.1021/jo00136a028

  日期：1982.7